Search research articles
Contact Us
Filters
Showing results (221-230 of 285) with videos related to
Page
of 29
Sort By:
Targeted Oncology
|
October 12, 2014
Panitumumab as a radiosensitizing agent in KRAS wild-type locally advanced rectal cancer
Feby Ingriani Mardjuadi, Javier Carrasco, Jean-Charles Coche, et al.
Annals of Surgical Oncology
|
March 25, 2017
TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG
Trevor Leong, B Mark Smithers, Karin Haustermans, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 4, 2025
Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: 10-Year Outcomes of the FLAME Trial
Karolína Menne Guricová, Cédric Draulans, Floris J Pos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 16, 2011
EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patients
Siwen Hu-Lieskovan, Daniel Vallbohmer, Wu Zhang, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
January 17, 2018
Standard whole prostate gland radiotherapy with and without lesion boost in prostate cancer: Toxicity in the FLAME randomized controlled trial
Evelyn M Monninkhof, Juliette W L van Loon, Marco van Vulpen, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
December 29, 2023
Clinical research for global needs of radiation oncology
Michael Baumann, Carol Bacchus, Marianne C Aznar, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
April 5, 2020
Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer
Cédric Draulans, Uulke A van der Heide, Karin Haustermans, et al.
The Lancet. Oncology
|
August 10, 2010
Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data
Monique Maas, Patty J Nelemans, Vincenzo Valentini, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
April 23, 2024
Towards a European prospective data registry for particle therapy
Cai Grau, Alexandru Dasu, Esther G C Troost, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 2, 2019
Pooled Analysis of external-beam RADiotherapy parameters in phase II and phase III trials in radiochemotherapy in Anal Cancer (PARADAC)
Eleonor Rivin Del Campo, Oscar Matzinger, Karin Haustermans, et al.
Page
of 29
Search research articles
Search
Showing results (221-230 of 285) with videos related to
Sort By:
Page
of 29
Targeted Oncology
|
October 12, 2014
Panitumumab as a radiosensitizing agent in KRAS wild-type locally advanced rectal cancer
Feby Ingriani Mardjuadi, Javier Carrasco, Jean-Charles Coche, et al.
Annals of Surgical Oncology
|
March 25, 2017
TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG
Trevor Leong, B Mark Smithers, Karin Haustermans, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 4, 2025
Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: 10-Year Outcomes of the FLAME Trial
Karolína Menne Guricová, Cédric Draulans, Floris J Pos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 16, 2011
EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patients
Siwen Hu-Lieskovan, Daniel Vallbohmer, Wu Zhang, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
January 17, 2018
Standard whole prostate gland radiotherapy with and without lesion boost in prostate cancer: Toxicity in the FLAME randomized controlled trial
Evelyn M Monninkhof, Juliette W L van Loon, Marco van Vulpen, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
December 29, 2023
Clinical research for global needs of radiation oncology
Michael Baumann, Carol Bacchus, Marianne C Aznar, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
April 5, 2020
Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer
Cédric Draulans, Uulke A van der Heide, Karin Haustermans, et al.
The Lancet. Oncology
|
August 10, 2010
Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data
Monique Maas, Patty J Nelemans, Vincenzo Valentini, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
April 23, 2024
Towards a European prospective data registry for particle therapy
Cai Grau, Alexandru Dasu, Esther G C Troost, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 2, 2019
Pooled Analysis of external-beam RADiotherapy parameters in phase II and phase III trials in radiochemotherapy in Anal Cancer (PARADAC)
Eleonor Rivin Del Campo, Oscar Matzinger, Karin Haustermans, et al.
Page
of 29